BCL9 and ductal breast carcinoma in situ: PDX DCIS MIND xenografts that showed invasive progression by the loss of SMA, expressed significantly higher BCL9 nuclear expression (Fig. 1g), showed significantly higher area of growth (Fig. 1h) and exhibited higher proliferation rate (Fig. 1i).